CA2495527A1 - New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof - Google Patents
New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof Download PDFInfo
- Publication number
- CA2495527A1 CA2495527A1 CA002495527A CA2495527A CA2495527A1 CA 2495527 A1 CA2495527 A1 CA 2495527A1 CA 002495527 A CA002495527 A CA 002495527A CA 2495527 A CA2495527 A CA 2495527A CA 2495527 A1 CA2495527 A1 CA 2495527A1
- Authority
- CA
- Canada
- Prior art keywords
- dysfunction
- compound
- cocoa powder
- pharmaceutical formulations
- containing rapid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000001880 Sexual dysfunction Diseases 0.000 title abstract 3
- 235000009470 Theobroma cacao Nutrition 0.000 title abstract 2
- 244000240602 cacao Species 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000843 powder Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Confectionery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A sexual-dysfunction-compound-containing rapid-onset pharmaceutical composition that comprises cocoa powder, process for manufacturing the composition and use of the composition in sexual dysfunction therapy.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202365A SE0202365D0 (en) | 2002-08-05 | 2002-08-05 | New formulation and use thereof |
SE0202365-3 | 2002-08-05 | ||
PCT/SE2003/001022 WO2004012702A1 (en) | 2002-08-05 | 2003-06-18 | New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2495527A1 true CA2495527A1 (en) | 2004-02-12 |
CA2495527C CA2495527C (en) | 2008-12-30 |
Family
ID=20288677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002495527A Expired - Fee Related CA2495527C (en) | 2002-08-05 | 2003-06-18 | New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1539096A1 (en) |
JP (1) | JP2005539008A (en) |
CN (1) | CN1674866B (en) |
AR (1) | AR040797A1 (en) |
AU (1) | AU2003239038B2 (en) |
BR (1) | BR0313224A (en) |
CA (1) | CA2495527C (en) |
IL (1) | IL166031A0 (en) |
MX (1) | MXPA05000978A (en) |
NZ (1) | NZ537520A (en) |
RU (1) | RU2312665C2 (en) |
SE (1) | SE0202365D0 (en) |
TW (1) | TW200418470A (en) |
WO (1) | WO2004012702A1 (en) |
ZA (1) | ZA200500051B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10232113A1 (en) | 2002-07-16 | 2004-01-29 | Bayer Ag | Medicinal products containing vardenafil hydrochloride trihydrate |
DE102005009241A1 (en) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Dosage forms with controlled bioavailability |
DE102005009240A1 (en) | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Dosage forms with improved pharmacokinetic properties |
GB0509317D0 (en) * | 2005-05-06 | 2005-06-15 | Clarke Anthony | Pharmaceutical formulation of apomorphine |
DE102010024866A1 (en) * | 2010-06-24 | 2011-12-29 | Pharmatech Gmbh | Formulation for taste masking |
ES2934136T3 (en) | 2016-09-21 | 2023-02-17 | Lts Lohmann Therapie Systeme Ag | oral dosage form |
EP3758675A1 (en) | 2018-03-01 | 2021-01-06 | LTS Lohmann Therapie-Systeme AG | Oral dosage form containing theobromine-free cocoa |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4755180A (en) * | 1986-06-16 | 1988-07-05 | Alza Corporation | Dosage form comprising solubility regulating member |
FR2717387B1 (en) * | 1994-03-17 | 1996-10-18 | Hi Pharmtech | Process for the production of chewable tablets based on troxerutin, calcium carbonate, calcium phosphate, arginine aspartate, amoxicillin arginine glutamate. |
US6121276A (en) | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
ES2105970B1 (en) * | 1995-08-02 | 1998-07-01 | S A L V A T Lab Sa | ORAL PHARMACEUTICAL COMPOSITION OF CIPROFLOXACINO, NON-AQUEOUS, STABLE AND WITH IMPROVED ORGANOLEPTIC CHARACTERISTICS. |
CA2178021C (en) * | 1996-04-19 | 1999-09-28 | Theodore H. Stanley | Tobacco substitute |
KR20000069899A (en) * | 1997-01-06 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | Rapidly releasing and taste-masking pharmaceutical dosage form |
GT199900061A (en) * | 1998-05-15 | 2000-10-14 | Pfizer | PHARMACEUTICAL FORMULATIONS. |
JP2000095710A (en) * | 1998-09-21 | 2000-04-04 | Taisho Pharmaceut Co Ltd | Oral solid preparation mixed with cacao powder |
JP2000119198A (en) * | 1998-10-16 | 2000-04-25 | Eisai Co Ltd | Phosphodiesterase inhibitor-containing peroral preparation hiding bitterness or the like |
US6060094A (en) * | 1998-10-30 | 2000-05-09 | Nestec S.A. | Method of reducing fat in fat-based coating for confectionery products |
SE9803986D0 (en) * | 1998-11-23 | 1998-11-23 | Pharmacia & Upjohn Ab | New compositions |
US6531114B1 (en) * | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
SI20109A (en) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stable pharmaceutical formulation |
US6291471B1 (en) | 1998-12-17 | 2001-09-18 | Abb Holdings, Inc. | Use of apomorphine for the treatment of organic erectile dysfunction in males |
US6455564B1 (en) * | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
AU779991B2 (en) | 1999-08-10 | 2005-02-24 | Board Of Regents, The University Of Texas System | Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight |
JP2001114668A (en) * | 1999-10-13 | 2001-04-24 | Meiji Seika Kaisha Ltd | Chocolate preparation |
PL366204A1 (en) | 1999-12-30 | 2005-01-24 | Tap Holdings, Inc. | Oral mucosal dosage forms of apomorphine |
AU2001273545A1 (en) | 2000-07-19 | 2002-01-30 | Lavipharm Laboratories, Inc. | Sildenafil citrate solid dispersions having high water solubility |
JP2002193839A (en) * | 2000-12-27 | 2002-07-10 | Meiji Seika Kaisha Ltd | Cocoa pharmaceutical preparation |
CA2435546A1 (en) * | 2001-02-08 | 2002-08-15 | Alice C. Martino | Rapid-onset medicament for the treatment of sexual dysfunction |
US20020172732A1 (en) * | 2001-03-21 | 2002-11-21 | Wies Ter Laak | Composition comprising cocoa |
-
2002
- 2002-08-05 SE SE0202365A patent/SE0202365D0/en unknown
-
2003
- 2003-06-18 CA CA002495527A patent/CA2495527C/en not_active Expired - Fee Related
- 2003-06-18 EP EP03733755A patent/EP1539096A1/en not_active Ceased
- 2003-06-18 RU RU2005102835/15A patent/RU2312665C2/en not_active IP Right Cessation
- 2003-06-18 NZ NZ537520A patent/NZ537520A/en not_active IP Right Cessation
- 2003-06-18 JP JP2004525901A patent/JP2005539008A/en active Pending
- 2003-06-18 CN CN038188910A patent/CN1674866B/en not_active Expired - Fee Related
- 2003-06-18 AU AU2003239038A patent/AU2003239038B2/en not_active Ceased
- 2003-06-18 MX MXPA05000978A patent/MXPA05000978A/en active IP Right Grant
- 2003-06-18 BR BR0313224-2A patent/BR0313224A/en not_active Application Discontinuation
- 2003-06-18 WO PCT/SE2003/001022 patent/WO2004012702A1/en active Application Filing
- 2003-07-25 TW TW092120418A patent/TW200418470A/en unknown
- 2003-08-05 AR AR20030102814A patent/AR040797A1/en not_active Application Discontinuation
-
2004
- 2004-12-28 IL IL16603104A patent/IL166031A0/en unknown
-
2005
- 2005-01-04 ZA ZA2005/00051A patent/ZA200500051B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003239038B2 (en) | 2008-01-03 |
RU2005102835A (en) | 2005-08-10 |
WO2004012702A1 (en) | 2004-02-12 |
TW200418470A (en) | 2004-10-01 |
IL166031A0 (en) | 2006-01-15 |
MXPA05000978A (en) | 2005-12-12 |
JP2005539008A (en) | 2005-12-22 |
ZA200500051B (en) | 2006-12-27 |
SE0202365D0 (en) | 2002-08-05 |
AR040797A1 (en) | 2005-04-20 |
RU2312665C2 (en) | 2007-12-20 |
CN1674866B (en) | 2012-09-26 |
EP1539096A1 (en) | 2005-06-15 |
CN1674866A (en) | 2005-09-28 |
AU2003239038A1 (en) | 2004-02-23 |
CA2495527C (en) | 2008-12-30 |
BR0313224A (en) | 2005-07-05 |
NZ537520A (en) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1478339E (en) | Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same | |
CA2461517A1 (en) | Nicotine formulations comprising cocoa and use thereof | |
AU2003233010A1 (en) | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof | |
HUP0402063A3 (en) | Indole-2-carboxamides process for producing them, pharmaceutical compositions containing them and use thereof | |
IL165977A (en) | Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same | |
IL219397A0 (en) | Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same | |
CA2458067A1 (en) | Use of flibanserin in the treatment of sexual disorders | |
WO2004055006A8 (en) | Novel compounds having selective inhibiting effect at gsk3 | |
HUP0202719A3 (en) | Pharmaceutical compositions for the treatment of female sexual dysfunctions | |
HK1098737A1 (en) | Process for the preparation of 1,1,1,3,3-pentafluoro-2-chloropropene and 1,1,1,3,3,3-hexafluoro-2-chloropropane | |
IL204947A0 (en) | Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them | |
AU2003289888A1 (en) | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | |
HUP0400246A3 (en) | 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use | |
HUP0301167A3 (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use | |
HK1067626A1 (en) | Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient | |
HUP0400200A3 (en) | Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof | |
AU2002238855A1 (en) | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same | |
HUP0400155A3 (en) | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same | |
IL161428A0 (en) | Oligoamine derivatives, methods for the production thereof and pharmaceutical compositions containing the same | |
WO2003059329A3 (en) | Polytartrate composition | |
CA2451519A1 (en) | Tablet comprising cetirizine and pseudoephedrine | |
CA2495527A1 (en) | New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof | |
CA2461757A1 (en) | Nicotine formulations comprising chocolate and use thereof | |
PT1358159E (en) | 3,4-diaminopyridine tartrate and phosphate, pharmaceutical compositions and uses thereof | |
WO2003075824A3 (en) | Process of manufacturing pharmaceutical composition useful for management of tuberculosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20160620 |